Countries Around the Globe Soften Their Stance on Cannabis use

Countries Around the Globe Soften Their Stance on Cannabis use

Countries all over the world such as Canada, Uruguay, Australia, and South Africa have already moved to fully legalize cannabis for medical use, as the topic continues to draw debate. Currently, cannabis is predominately being used to treat chronic pain among patients as an alternative to opioids. However, cannabis is also being leveraged to treat maladies like cancer, epilepsy, Alzheimer’s, and various mental conditions. The beneficial health effects of cannabis have even prompted South Korea to legalize certain medicinal cannabis treatments, making it the first East Asian country to allow the plant’s medical use in some form. The legalization in South Korea marks a major milestone for the global industry, considering the harshly enforced regulations in East Asian culture. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023.

Additionally, the market is projected to register a robust CAGR of 37% during the forecast period as well. The market is predominately being accelerated by the widespread legalization efforts currently ongoing around the globe. Mainly, countries are exploring opportunities within the medical sector, however, other nations like the U.S. and Canada are expected to dominate the recreational sector. Weekend Unlimited Inc. (OTC: WKULF) (CSE: POT), Liberty Health Sciences Inc (OTC: LHSIF) (CSE:LHS), VIVO Cannabis Inc. (OTC: VVCIF) (TSX-V: VIVO), Nightfood Holdings, Inc. (OTC: NGTF), Baristas Coffee Company Inc. (OTC: BCCI)

The matter of legality revolving around cannabis in Asia is uncertain, however, multiple countries in Europe and South America have already legalized, or are moving to, legalize cannabis on some level. Many are beginning to understand the beneficial and therapeutic effects of cannabis, which is prompting countries to consider the plant as a legitimate medical treatment.

As research and development continue to progress, more nations are projected to move to legalize cannabis. However, certain regions view medical cannabis through different lenses, varying on their tolerance of flower and oil use or which medical condition the plant can be used to treat. Despite the restrictions, the broad adoption of medical cannabis is allowing the industry to grow gradually. “The vast majority of [medical marijuana programs] look completely different from the U.S. You can’t go in and buy a gummy bear and have that be considered medicine. The Canadian approach to regulation and product differentiation is much more reflective of what we’re likely to see internationally,” said Bethany Gomez, Director of Research for Brightfield Group, via Forbes, “Every country is going to be cautious about legalizing a drug that has been demonized for so many years,” she said.

Weekend Unlimited Inc. (OTC: WKULF) (CSE: POT) is also listed on the Canadian Securities Exchange under the ticker (CSE: POT). Yesterday, the Company announced, “the signing of a definitive agreement on 13 February 2019 to acquire R&D Pharma’s Jamaican interests, has completed the arms-length acquisition of R&D Pharma.

‘We are thrilled to join the tremendous team at Weekend Unlimited under Paul Chu’s leadership. With our Tier-3 cultivators license, our active focus is on medical tourism in Jamaica, having designed and constructed the first of our ‘Ganja Café’s’ within a short tour bus ride from the cruise ship terminals in Ocho Rios,’ said Richard Bailey, President of R&D Pharma.

‘We just completed a harvest last week on our 98-acre property to stock the Ganja Café for first tourism visits beginning on May 15th. The Ganja Café will be stocked with branded Jamaican strains, extracts, and infused products that will serve as a precursor to our future wholesale distribution in Jamaica and internationally,’ added Mr. Bailey.

Weekend issued 80 million shares at a deemed price of $0.25 as well as making available 25 million warrants to the shareholders of R & D Pharma. Each warrant entitles the holder to acquire an additional share for $0.35 for a period of 2 years. Approximately 49 million shares are subject to a voluntary escrow agreement that sees 20% released at closing and the balance in 6 equal instalments over 3 years.


Previous articleHodge Podge: A smattering of thoughts…
Next articleGreatest Albums Live at the Penticton Trade And Convention Centre


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.